James Reed, MD
Internal Medicine · San Francisco, CANPI 1851451934
Payments from drug & device makers
Across 78 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$279
- Gilead$208
- Pfizer$173
- Takeda Pharmaceuticals U.S.A., Inc.$145
- QOL Medical, LLC$141
- Ferring Pharmaceuticals Inc.$123
- plus $482 from 10 others
What the payments were for
- Food & beverage$1,51498%
- Education$201%
- Gifts$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $279 |
| Gilead | 9 | $208 |
| Pfizer | 8 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $145 |
| QOL Medical, LLC | 7 | $141 |
| Ferring Pharmaceuticals Inc. | 6 | $123 |
| Medtronic | 2 | $93 |
| Braintree Laboratories, Inc. | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $67 |
| Lilly USA, LLC | 2 | $65 |
| Celltrion USA Inc. | 2 | $47 |
| Johnson & Johnson | 2 | $47 |
| Boehringer Ingelheim | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
How this compares
$1,551 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 21 | $11,718 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 105 | $6,441 |
| Pantoprazole Sodium | 109 | $1,406 |
| Sucralfate | 21 | $1,016 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 33 | $426 |
| Omeprazole | 17 | $216 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.